A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

A recent study reveals a link between belly fat and psoriasis, especially in women. Researchers analyzed data from UK Biobank ...

FULL STORY. Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women.

If psoriasis is poorly controlled, the body’s levels of inflammatory cytokines go up. The inflammatory response is often easy to spot with skin plaques. But there’s more going on under the ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed. At week 8 ...

Potential Positives. ZORYVE foam 0.3% demonstrated significant efficacy in treating psoriasis, with 66.4% of individuals achieving scalp success and 45.5% achieving body success at Week 8.

Fat around the abdomen is more strongly linked to psoriasis risk that total body fat, particularly in women. “Our research shows that where fat is stored in the body matters when it comes to ...

There’s no cure for psoriasis, but treatment, such as red light therapy (RLT), can help ease its symptoms. Learn if RLT is right for you.

The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) topical foam, 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients aged 12 ...

Source Reference: Gooderham MJ, et al "Roflumilast foam, 0.3%, for psoriasis of the scalp and body: The ARRECTOR phase 3 randomized clinical trial" JAMA Dermatol 2025; DOI: 10.1001/jamadermatol ...